511 related articles for article (PubMed ID: 11883865)
21. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.
Pilli T; Brianzoni E; Capoccetti F; Castagna MG; Fattori S; Poggiu A; Rossi G; Ferretti F; Guarino E; Burroni L; Vattimo A; Cipri C; Pacini F
J Clin Endocrinol Metab; 2007 Sep; 92(9):3542-6. PubMed ID: 17609306
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).
Meier CA; Braverman LE; Ebner SA; Veronikis I; Daniels GH; Ross DS; Deraska DJ; Davies TF; Valentine M; DeGroot LJ
J Clin Endocrinol Metab; 1994 Jan; 78(1):188-96. PubMed ID: 8288703
[TBL] [Abstract][Full Text] [Related]
23. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
24. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
25. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
26. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
27. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
[TBL] [Abstract][Full Text] [Related]
28. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
Perros P
J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
[TBL] [Abstract][Full Text] [Related]
29. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
31. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients.
Rosario PW; Xavier AC; Calsolari MR
Thyroid; 2010 Nov; 20(11):1247-52. PubMed ID: 20950256
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
Kohlfuerst S; Igerc I; Lind P
Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium.
Barbaro D; Grosso M; Boni G; Lapi P; Pasquini C; Orsini P; Turco A; Meucci G; Marzola MC; Berti P; Miccoli P; Mariani G; Rubello D
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):242-9. PubMed ID: 19760415
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
38. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
39. Successful use of recombinant human thyrotropin in the therapy of pediatric well-differentiated thyroid cancer.
Ralli M; Cohan P; Lee K
J Endocrinol Invest; 2005 Mar; 28(3):270-3. PubMed ID: 15952413
[TBL] [Abstract][Full Text] [Related]
40. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.
Luster M; Handkiewicz-Junak D; Grossi A; Zacharin M; Taïeb D; Cruz O; Hitzel A; Casas JA; Mäder U; Dottorini ME;
J Clin Endocrinol Metab; 2009 Oct; 94(10):3948-53. PubMed ID: 19773393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]